Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer

ConferenceIBTROZIPositive

AI Analysis

Summary

Nuvation Bio announced new analyses of pooled data from TRUST-I and TRUST-II studies demonstrating consistent efficacy of IBTROZI (taletrectinib) across key patient subgroups in advanced ROS1+ NSCLC, presented at the 2026 World Conference on Lung Cancer.

Clinical Trial Data

Primary Endpoint

Met

Importance:5/10

Sentiment:

0.70

IBTROZItaletrectinibROS1+ NSCLCTRUST-ITRUST-IIefficacy datasubgroup analysisWorld Conference on Lung Cancer

Related Companies

$NUVB-WT

Read the original article

Published by PR Newswire Biotech on September 15, 2026 12:00 PM

Read Original